Cleare, Anthony J, Reid, Steven, Chalder, Trudie et al. · BMJ clinical evidence · 2015
Quick Summary
This research review looked at treatments for chronic fatigue syndrome (ME/CFS) and found that the condition affects between 0.006% and 3% of people depending on how it's diagnosed, with women more commonly affected than men. The researchers searched multiple medical databases for studies on four main treatments: antidepressants, cognitive behavioral therapy (a type of talk therapy), corticosteroids (anti-inflammatory drugs), and graded exercise therapy. They carefully reviewed 15 high-quality studies to evaluate how well these treatments work and whether they're safe.
Why It Matters
This systematic review is important because ME/CFS affects a significant proportion of the population and currently lacks universally effective treatments. By synthesizing evidence from multiple high-quality studies, this overview provides clinicians and patients with a comprehensive assessment of which treatments have scientific support, helping guide treatment decisions and research priorities.
Observed Findings
- ME/CFS prevalence ranges from 0.006% to 3% depending on diagnostic criteria used
- Women have higher risk of developing ME/CFS than men
- Four main interventions were identified for systematic evaluation: antidepressants, cognitive behavioral therapy, corticosteroids, and graded exercise therapy
- GRADE methodology was applied to assess evidence quality for 23 different treatment comparisons
- Initial database search identified 169 studies, with only 15 meeting inclusion criteria for detailed analysis
Inferred Conclusions
- The evidence base for ME/CFS treatments is limited, with considerable variation in study quality and design
- Different interventions have varying levels of evidence support depending on patient populations and outcome measures studied
- More rigorous, well-designed randomized controlled trials are needed to establish definitive treatment effectiveness
- Standardized diagnostic criteria for ME/CFS would improve consistency and comparability of treatment research
Remaining Questions
- Why do some patients respond to certain treatments while others do not, and what patient characteristics predict treatment response?
What This Study Does Not Prove
This review does not establish which single treatment is universally most effective, as the strength of evidence varies across interventions and patient subgroups. It also does not prove causation or explain the biological mechanisms underlying why these treatments may or may not work for ME/CFS, nor does it address long-term outcomes beyond the timeframes studied in individual trials.